Technical Principle
Irreversible Electroporation (IRE) Technology
Irreversible electroporation operates by applying high-voltage electric fields through a pulse generator that delivers microsecond-duration electric pulses. This induces transmembrane potential formation on cell membranes, locally overcoming the dielectric strength of phospholipid bilayers. The process creates hydrophilic nanopores (nanometer-scale pores) within the lipid bilayer, altering membrane permeability. When energy exceeds threshold levels, it causes permanent membrane permeabilization, disrupting intracellular homeostasis and triggering programmed cell apoptosis.
Key Features of Irreversible Electroporation (IRE) Technology
1. Non-Thermal Ablation : Ensures procedural safety with no anatomical restrictions, Eliminates risk of rectal fistula associated with traditional thermal ablation.
2. High Tissue Selectivity : Preserves vascular structures and neural bundles within ablation zones,Maintains sexual function and urinary continence in prostate cancer patients.
3. Ultra-Minimally Invasive : Requires only 1mm-diameter needles (sub-millimeter scale).
Applications
Indicated for ablation therapy in medical institutions for adult male patients with low- to intermediate-risk localized prostate cancer meeting all criteria
(PSA＜20ng/ml、T1a-T2c、Gleason Score ≤7)
Product Advantages
High-Frequency Irreversible Electroporation (H-FIRE, a new-generation IRE technology)
therapeutic device features four significant advantages.
More Complete Ablation
Well-Demarcated Boundaries
Induces near-total cellular apoptosis (≈100%) within the ablation zone
Urinary Continence
Tissue-Selective Ablation
Clinically Prevents Urethral Trauma and Nerve Injury to Continence-Governed Structures
Sexual Function
Precision Preservation of Sexual Function via Clinically Insignificant Impact on Neurovascular Structures
Ultra-Minimally Invasive
Streamlined Operation
Short Procedure Time
Minimal Bleeding & Complications
CSCO Prostate Cancer Diagnosis and Treatment Guidelines 2024
- Anterior
PlacementIntermediate-Risk Localized
Grade Group2(CSCO 2B） - Additional
OptionLow-Risk Localized
Grade Group3(CSCO 3B） - Anterior
PlacementLow-Risk Localized
Grade Group3(CSCO 3B） - Additional
OptionRecurrence After Definitive Radiotherapy
PSADT< 9months
Grade Group3(CSCO 3B）
- Additional
OptionRecurrence After Definitive Radiotherapy
PSADT> 9months
Grade Group2(CSCO 3B）
Product Configuration
| No. | Component | Component Model Number |
|---|---|---|
| 1 | Rack-Mounted Main Control Unit (with Integrated Display) | IRE-PCa-01-A |
| 2 | Bottom Rack Space for Main Control Unit | IRE-PCa-01-B |
| 3 | Footswitch | HRF-M5Y/A |
| 4 | Inter-cabinet signal cable | PT-CNT-36A |
| 5 | Inter-cabinet power cable | / |
| 6 | AC power cable | / |
